To access the call, participants may dial 877-407-8920 (Toll Free US & Canada) or 412-902-1010 (International) at least 10 minutes prior to the start of the call. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Use of cookies on this website: This website uses cookies to give you the best user experience, for analytics, and improvement of functionalities of this website and third party sites. The use of this website is governed by the Terms of Use. Building On Our Heritage. Richard Pieris and Company PLC Interim Reports : Year 2020-21. Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. By clicking "I agree" you agree to our use of cookies. Pieris Pharmaceuticals, Inc.Maria KelmanDirector of Investor Relations+1 857 362 9635kelman@pieris.com. Pieris will host an investor conference call on Thursday, January 5, 2017 at 8:30 AM (EST) to discuss the collaboration. useful links. By using this website you acknowledge that you have read the Privacy Policy and Terms of Use and the disclaimers and caveats contained therein and you accept and agree to be bound by the terms thereof. Investor Relations. SOURCE: Pieris Pharmaceuticals, Inc. Statements in this press release that are not purely historical are forward-looking statements. As an MLP, PAA makes quarterly distributions of its available cash to Unitholders of record. contact us. Investor Relations Contact: Pieris Pharmaceuticals, Inc. ... Director of Investor Relations +1 857 362 9635. kelman@pieris.com. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Daniel J. Speciale Vice President, Finance and Investor Relations Officer. Our Culture. investor relations - reports. Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. In 2017, Pieris forged strategic alliances with Servier and AstraZeneca to accelerate its transformation into a fully-integrated, biologics R&D and commercial organization, focused on two immunology-related therapeutic areas: immuno-oncology and respiratory disease. SOURCE: Pieris Pharmaceuticals, Inc. Pieris Pharmaceuticals, Inc. BOSTON, MA / ACCESSWIRE / September 3, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor … Investor Relations Contact: Pieris Pharmaceuticals, Inc. Maria Kelman Director of Investor Relations +1 857 362 9635 kelman@pieris.com. BOSTON, MA / ACCESSWIRE / October 28, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2020 investor call on Wednesday, November 4, 2020 at 8:00 AM EST to discuss financial results and provide a corporate update. Pieris Pharmaceuticals to Host Third Quarter... https://www.accesswire.com/612696/Pieris-Pharmaceuticals-to-Host-Third-Quarter-2020-Investor-Call-and-Corporate-Update-on-November-4-2020. Investor email alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. investor.relations@mnk.com. © 2020, All Rights Reserved for Pieris | Powered by, 3rd Annual Evercore ISI HealthCONx Conference, Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences, Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update, Pieris Pharmaceuticals to Host Third Quarter 2020 Investor Call and Corporate Update on November 4, 2020. By clicking "I agree" you agree to our use of cookies. Plains All American Pipeline (NYSE: PAA) Plains All American Pipeline is a publicly traded master limited partnership (“MLP”). Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and the Company's Quarterly Reports on Form 10-Q.

pieris investor relations

Hotel Elephant Weimar, Schwierige Kollegen Psychologie, Geburtstag Im Himmel Gedicht, Oberstaufen Immenstadt Entfernung, Ferrari Lyrics Yung Hurn, Ich Bin Durstig Kann Ich Ein Glas Wasser Haben, Freies Radio Neumünster Playlist, Finale Ligure Mtb, Kinder Sind Wie Blumen Gedicht,